by dvcr23 | Sep 6, 2023 | Uncategorized
OVERLAND PARK, Kan.; September 6, 2023 – Dr. Vince Clinical Research (DVCR), a full-service clinical research organization (CRO), today announced the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III dose-optimization onset and duration laboratory classroom...
by Salvador Solis | Aug 29, 2023 | Uncategorized
Strategic collaboration amplifies accessibility to Clario’s Early Precision QT (EPQT) methodology, enabling biopharmaceutical firms to secure more accurate and cost-efficient cardiac safety data in early clinical development stages. Meticulous multi-stage evaluation...
by Salvador Solis | Aug 2, 2023 | Uncategorized
OVERLAND PARK, Kan.; August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study...
by enewman | Jun 27, 2023 | Uncategorized
OVERLAND PARK, Kan.; June 27, 2023 (Business Wire) – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes...
by Salvador Solis | Jan 11, 2023 | Uncategorized
OVERLAND PARK, KS; January 10, 2023—(BUSINESS WIRE) Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending...
by enewman | Dec 9, 2022 | Uncategorized
OVERLAND PARK, KS, December 12, 2022 (Globe Newswire) – Dr. Vince Clinical Research (DVCR) announced the addition of highly experienced investigator George J. Atiee, M.D. to the medical team at its world-class clinical pharmacology unit. Dr. Atiee has been...
Recent Comments